In these aggressive tumors, E-cadherin was highly expressed in both primary lesions and intralymphatic tumor emboli, thus challenging the common notion that E-cadherin loss correlates with poor prognosis in carcinomas. The gene discussed is CDH1; the disease is carcinoma.